Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review.

Left atrium mass in a patient with breast cancer: a case report. J Med Case Rep (2016) 0.75

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.99

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost (2005) 5.92

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.29

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.02

Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37

Risk assessment for recurrent venous thrombosis. Lancet (2010) 3.31

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29

Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med (2013) 2.84

Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol (2014) 2.18

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07

Interactions of warfarin with drugs and food. Ann Intern Med (1994) 1.88

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol (2013) 1.69

New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.59

Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med (2014) 1.57

Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardiol (2014) 1.55

Oral anticoagulant therapies: balancing the risks. Am J Health Syst Pharm (2013) 1.43

A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists. Am J Cardiol (2014) 1.42

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost (2008) 1.38

New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc (2014) 1.37

How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood (2012) 1.31

Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol (2009) 1.27

Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy (2009) 1.19

"Resistance" to warfarin due to unrecognized vitamin K supplementation. N Engl J Med (1980) 1.14

A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost (2012) 1.10

Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis (2015) 1.01

Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost (2013) 1.00

Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica (2006) 0.99

Vitamin K deficiency from dietary vitamin K restriction in humans. Am J Clin Nutr (1988) 0.89

Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis (2011) 0.84

Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? Curr Cardiol Rep (2014) 0.82

Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost (2010) 0.80

Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with constant vitamin K1 content. Thromb Haemost (1997) 0.78

A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention. Postgrad Med (2013) 0.78